Literature DB >> 14748727

Scavenger receptor class B type I in high-density lipoprotein metabolism, atherosclerosis and heart disease: lessons from gene-targeted mice.

B Trigatti1, S Covey, A Rizvi.   

Abstract

The scavenger receptor class B type I (SR-BI) is a multi-ligand receptor that can mediate the binding and bi-directional lipid transfer between high-density lipoproteins (HDLs) and cells. It is expressed in a variety of tissues, including the liver, and in macrophages in atherosclerotic plaques. The physiological role of SR-BI has been tested in vivo by the genetic manipulation of SR-BI levels in mice. Mice lacking SR-BI exhibit impaired hepatic-selective HDL cholesterol uptake and increased atherosclerosis, suggesting that SR-BI is required for hepatic reverse cholesterol transport and normally protects against atherosclerosis. Surprisingly, elimination of SR-BI in apolipoprotein E knockout mice results in rapid development of occlusive coronary artery disease, accompanied by spontaneous myocardial infarction, reduced heart function and early death, which points to a role for SR-BI in protection against coronary heart disease. The in vivo role of macrophage SR-BI has been less clear. We have used bone-marrow transplantation to demonstrate that bone-marrow-derived SR-BI also normally protects against atherosclerosis in low-density lipoprotein receptor knockout mice. These results suggest that SR-BI may have multiple protective effects against atherosclerosis in different tissues.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14748727     DOI: 10.1042/bst0320116

Source DB:  PubMed          Journal:  Biochem Soc Trans        ISSN: 0300-5127            Impact factor:   5.407


  8 in total

Review 1.  Pharmacomodulation of high-density lipoprotein metabolism as a therapeutic intervention for atherosclerotic disease.

Authors:  Peter P Toth
Journal:  Curr Cardiol Rep       Date:  2010-11       Impact factor: 2.931

2.  The membrane lipid phosphatidylcholine is an unexpected source of triacylglycerol in the liver.

Authors:  Jelske N van der Veen; Susanne Lingrell; Dennis E Vance
Journal:  J Biol Chem       Date:  2012-05-18       Impact factor: 5.157

3.  Baicalin promotes cholesterol efflux by regulating the expression of SR-BI in macrophages.

Authors:  Renchao Yu; Yuexia Lv; Juanling Wang; Nana Pan; Rui Zhang; Xiaxia Wang; Haichu Yu; Lijuan Tan; Yunhe Zhao; Bo Li
Journal:  Exp Ther Med       Date:  2016-11-08       Impact factor: 2.447

4.  Increased plasma cholesterol esterification by LCAT reduces diet-induced atherosclerosis in SR-BI knockout mice.

Authors:  Seth G Thacker; Xavier Rousset; Safiya Esmail; Abdalrahman Zarzour; Xueting Jin; Heidi L Collins; Maureen Sampson; John Stonik; Stephen Demosky; Daniela A Malide; Lita Freeman; Boris L Vaisman; Howard S Kruth; Steven J Adelman; Alan T Remaley
Journal:  J Lipid Res       Date:  2015-05-11       Impact factor: 5.922

Review 5.  Will torcetrapib be the next big thing in coronary heart disease risk reduction?

Authors:  James M McKenney; John A Hoekstra
Journal:  Curr Atheroscler Rep       Date:  2007-01       Impact factor: 5.113

Review 6.  Primary genetic disorders affecting high density lipoprotein (HDL).

Authors:  Constantine E Kosmas; Delia Silverio; Andreas Sourlas; Frank Garcia; Peter D Montan; Eliscer Guzman
Journal:  Drugs Context       Date:  2018-09-11

Review 7.  Dysfunctional High-Density Lipoprotein: An Innovative Target for Proteomics and Lipidomics.

Authors:  Juan Salazar; Luis Carlos Olivar; Eduardo Ramos; Mervin Chávez-Castillo; Joselyn Rojas; Valmore Bermúdez
Journal:  Cholesterol       Date:  2015-11-08

8.  Control of Cholesterol Metabolism Using a Systems Approach.

Authors:  Dorota Formanowicz; Marcin Radom; Agnieszka Rybarczyk; Krzysztof Tanaś; Piotr Formanowicz
Journal:  Biology (Basel)       Date:  2022-03-11
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.